Equities Analysts Issue Forecasts for XFOR FY2029 Earnings

Key Points

• Brookline Capital Markets raised its FY2029 EPS forecast for X4 Pharmaceuticals to $0.99 from $0.88, while the current full-year consensus remains a loss of $0.77 per share.
• X4 exceeded quarterly expectations, reporting an EPS loss of $0.13 versus the estimated $0.18 loss, and generated $8.81 million in revenue compared with the $2.42 million consensus estimate.
• Analyst sentiment is generally positive, with five Buy ratings, one Hold, and one Sell, producing a “Moderate Buy” consensus and an average price target of $9.70 versus the stock’s recent $4.64 price.

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Research analysts at Brookline Capital Markets boosted their FY2029 earnings per share estimates for shares of X4 Pharmaceuticals in a report released on Thursday, August 6th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of $0.99 per share for the year, up from their previous forecast of $0.88. The consensus estimate for X4 Pharmaceuticals' current full-year earnings is ($0.77) per share.

X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative return on equity of 64.95% and a negative net margin of 568.80%.The business had revenue of $8.81 million during the quarter, compared to analyst estimates of $2.42 million.

XFOR has been the subject of several other reports. Leerink Partners initiated coverage on X4 Pharmaceuticals in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $12.00 price target for the company. Weiss Ratings raised X4 Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 28th. Finally, Wells Fargo & Company began coverage on X4 Pharmaceuticals in a research note on Friday, July 10th. They issued an "overweight" rating and a $11.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $9.70.

X4 Pharmaceuticals Stock Performance

XFOR opened at $4.64 on Monday. X4 Pharmaceuticals has a one year low of $1.35 and a one year high of $4.83. The business's 50 day moving average price is $4.02 and its 200 day moving average price is $3.94. The stock has a market capitalization of $437.64 million, a PE ratio of -3.87 and a beta of 0.37. The company has a debt-to-equity ratio of 0.45, a quick ratio of 9.98 and a current ratio of 10.18.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE boosted its stake in shares of X4 Pharmaceuticals by 20.3% during the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company's stock worth $98,000 after buying an additional 22,485 shares during the period. Rhumbline Advisers increased its position in X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company's stock valued at $44,000 after acquiring an additional 9,690 shares during the period. Jane Street Group LLC increased its position in X4 Pharmaceuticals by 112.5% in the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company's stock valued at $185,000 after acquiring an additional 51,544 shares during the period. Vanguard Group Inc. raised its stake in X4 Pharmaceuticals by 77.0% during the 3rd quarter. Vanguard Group Inc. now owns 410,485 shares of the company's stock valued at $1,404,000 after acquiring an additional 178,593 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new stake in X4 Pharmaceuticals during the 3rd quarter valued at approximately $47,000. 72.03% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at X4 Pharmaceuticals

In other news, CFO David Kirske sold 8,543 shares of the firm's stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total transaction of $36,393.18. Following the transaction, the chief financial officer directly owned 167,750 shares in the company, valued at approximately $714,615. This trade represents a 4.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.13% of the company's stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company's lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström's macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source